SOUTH SAN FRANCISCO, CA--(Marketwire - April 29, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the first quarter of 2008. Net loss for the first quarter of 2008 was $13.9 million, or $0.28 per share. As of March 31, 2008, cash, cash equivalents, restricted cash and long-term investments totaled $128.8 million.
